Patents by Inventor Jason A. Duquette

Jason A. Duquette has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11161000
    Abstract: A portable water storage system for draining and refilling building fire protection systems is provided. The system includes a tank for storing fire protection system water, a hose connecting the building fire protection system to the tank. A vacuum pump is configured to draw a low pressure on the fire protection system. A water pump is configured to return the water of the fire protection system from the tank to the system.
    Type: Grant
    Filed: April 14, 2020
    Date of Patent: November 2, 2021
    Inventors: Jason Payton, Mike Payton, Tim Duquette
  • Patent number: 11144454
    Abstract: Metadata in volatile memory is selectively compressed and destaged to non-volatile storage in the event of an emergency shutdown due to loss of like power. Compression offload hardware that is normally used for data compression is used to compress the metadata, e.g. at line speed. The compressed metadata and any uncompressed metadata that was not selected for compression may be destaged to vault drives along with compressed and uncompressed data that is in the volatile memory. Compression during vaulting may decrease power consumption when operating under standby battery power.
    Type: Grant
    Filed: November 22, 2019
    Date of Patent: October 12, 2021
    Assignee: Dell Products L.P.
    Inventors: James Guyer, Jason Duquette
  • Patent number: 11122121
    Abstract: A storage system includes four storage engines, each storage engine including two compute nodes. Eight point-to-point connections are used to interconnect pairs of compute nodes on different storage engines, such that each compute node is connected to exactly two other compute nodes of the storage system. Atomic operations can be initiated by any compute node on any other compute node. Atomic operations received by a compute node on one of the point-to-point connections will be forwarded on the other point-to-point connection if the atomic operation is not directed to the compute node. During normal operation, atomic operations on a given compute node are performed on a host adapter associated with the compute node. Upon failure of the host adapter associated with the compute node, atomic operations may be performed on the compute node using the host adapter of the other compute node of the storage engine.
    Type: Grant
    Filed: November 22, 2019
    Date of Patent: September 14, 2021
    Assignee: EMC IP Holding Company LLC
    Inventors: James Guyer, Alesia Tringale, Jason Duquette, William Baxter
  • Publication number: 20210230189
    Abstract: Provided herein are myeloid cell leukemia 1 protein (Mcl-1) inhibitors, methods of their preparation, related pharmaceutical compositions, and methods of using the same. For example, provided herein are compounds of Formula I, and pharmaceutically acceptable salts thereof and pharmaceutical compositions containing the compounds. The compounds and compositions provided herein may be used, for example, in the treatment of diseases or conditions, such as cancer.
    Type: Application
    Filed: February 24, 2017
    Publication date: July 29, 2021
    Applicant: AMGEN INC.
    Inventors: Sean P. BROWN, David Karl BEDKE, Micheal R. DEGRAFFENREID, Jiasheng FU, Zhihong LI, Felix GONZALEZ LOPEZ TURISO, Ana GONZALEZ BUENROSTRO, Micheal W. GRIBBLE, JR., Micheal G. JOHNSON, Todd J. KOHN, Kexue LI, Yunxiao LI, Mike Elias LIZARZABURU, Yosup REW, Joshua TAYGERLY, Yingcal WANG, Xuelei YAN, Ming YU, Jiang ZHU, Manuel ZANCANELLA, Xian Yun JIAO, Liusheng ZHU, Xianghong WANG, Julio C. MEDINA, Jason A. DUQUETTE, Jonathan B. HOUZE, Marc VIMOLRATANA, Marlo G. CARDOZO, Alan C. CHENG
  • Publication number: 20210179560
    Abstract: The present invention provides MDM2 inhibitor compounds of Formula I, wherein the variables are defined above, which compounds are useful as therapeutic agents, particularly for the treatment of cancers. The present invention also relates to pharmaceutical compositions that contain an MDM2 inhibitor.
    Type: Application
    Filed: August 3, 2020
    Publication date: June 17, 2021
    Inventors: Michael D. Bartberger, Ana Gonzalez Buenrostro, Hilary Plake Beck, Xiaoqi Chen, Richard Victor Connors, Jeffrey Deignan, Jason A. Duquette, I, John Eksterowicz, Benjamin Fisher, Brian M. Fox, Jiasheng Fu, Zice Fu, Felix Gonzalez Lopez De Turiso, Michael W. Gribble, Darin J. Gustin, Julie A. Heath, Xin Huang, XianYun Jiao, Michael G. Johnson, Frank Kayser, David John Kopecky, SuJen Lai, Yihong Li, Zhihong Li, Jiwen Liu, Jonathan D. Low, Brian S. Lucas, Zhihua MA, Lawrence R. McGee, Joel McIntosh, Dustin L. McMinn, Julio C. Medina, Jeffrey Thomas Mihalic, Steven H. Olson, Yossup Rew, Philip M. Roveto, Daqing Sun, Xiaodong Wang, Yingcai Wang, Xuelei Yan, Ming Yu, Jiang Zhu
  • Publication number: 20210163402
    Abstract: Compounds are provided having the structure of Formula (I): or a pharmaceutically acceptable isomer, racemate, hydrate, solvate, isotope, or salt thereof, wherein A, B, L, R3, R4, R5, R6, R8, m and n are as defined herein. Such compounds modulate the opioid receptor, particulare the mu-opioid receptor (MOR) and/or the kappa-opioid receptor (KOR), and/or the delta-opioid receptor (DOR). Products containing such compounds, as well as methods for their use and preparation, are also provided.
    Type: Application
    Filed: July 10, 2020
    Publication date: June 3, 2021
    Inventors: Julio Cesar Medina, Lawrence R McGee, Zhi-Liang Wei, Corinne Sadlowski, Frederick Seidl, Ulhas Bhatt, Xiaodong Wang, Thomas Nguyen, David Sperandio, Pingyu Ding, Alok Nerurkar, Yihong Li, Jason Duquette
  • Publication number: 20210157487
    Abstract: A storage system includes four storage engines, each storage engine including two compute nodes. Eight point-to-point connections are used to interconnect pairs of compute nodes on different storage engines, such that each compute node is connected to exactly two other compute nodes of the storage system. Atomic operations can be initiated by any compute node on any other compute node. Atomic operations received by a compute node on one of the point-to-point connections will be forwarded on the other point-to-point connection if the atomic operation is not directed to the compute node. During normal operation, atomic operations on a given compute node are performed on a host adapter associated with the compute node. Upon failure of the host adapter associated with the compute node, atomic operations may be performed on the compute node using the host adapter of the other compute node of the storage engine.
    Type: Application
    Filed: November 22, 2019
    Publication date: May 27, 2021
    Inventors: James Guyer, Jason Duquette, Alesia Tringale, Sean Pollard, Julie Zhivich, Jinxian Xian, William Baxter
  • Publication number: 20210157726
    Abstract: Metadata in volatile memory is selectively compressed and destaged to non-volatile storage in the event of an emergency shutdown due to loss of like power. Compression offload hardware that is normally used for data compression is used to compress the metadata, e.g. at line speed. The compressed metadata and any uncompressed metadata that was not selected for compression may be destaged to vault drives along with compressed and uncompressed data that is in the volatile memory. Compression during vaulting may decrease power consumption when operating under standby battery power.
    Type: Application
    Filed: November 22, 2019
    Publication date: May 27, 2021
    Applicant: EMC IP HOLDING COMPANY LLC
    Inventors: James Guyer, Jason Duquette
  • Publication number: 20210160316
    Abstract: A storage system includes four storage engines, each storage engine including two compute nodes. Eight point-to-point connections are used to interconnect pairs of compute nodes on different storage engines, such that each compute node is connected to exactly two other compute nodes of the storage system. Atomic operations can be initiated by any compute node on any other compute node. Atomic operations received by a compute node on one of the point-to-point connections will be forwarded on the other point-to-point connection if the atomic operation is not directed to the compute node. During normal operation, atomic operations on a given compute node are performed on a host adapter associated with the compute node. Upon failure of the host adapter associated with the compute node, atomic operations may be performed on the compute node using the host adapter of the other compute node of the storage engine.
    Type: Application
    Filed: November 22, 2019
    Publication date: May 27, 2021
    Inventors: James Guyer, Alesia Tringale, Jason Duquette, William Baxter
  • Publication number: 20210147343
    Abstract: Compounds are provided having the structure of Formula (I): or a pharmaceutically acceptable isomer, racemate, hydrate, solvate, isotope, or salt thereof, wherein A, B, L, R3, R4, R5, R6, R8, m and n are as defined herein. Such compounds modulate the opioid receptor, particulate the mu-opioid receptor (MOR) and/or the kappa-opioid receptor (KOR), and/or the delta-opioid receptor (DOR). Products containing such compounds, as well as methods for their use and preparation, are also provided.
    Type: Application
    Filed: April 4, 2019
    Publication date: May 20, 2021
    Inventors: Julio Cesar MEDINA, Larry McGEE, Zhi-Liang WEI, Corinne SADLOWSKI, Frederick SEIDL, Ulhas BHATT, Xiaodong WANG, Thomas NGUYEN, David SPERANDIO, Pingyu DING, Alok NERURKAR, Yihong LI, Jason DUQUETTE
  • Publication number: 20210064659
    Abstract: A hardware offload includes a hash engine that performs hashing for a block-based storage system. The hash engine calculates multiple hash values for each input buffer provided by the storage system. The hash values may be calculated with variably offset and overlapping portions of the input buffer, wherein each portion is larger than the native block size of the storage system. The hardware offload may also include a compression engine that performs compression on the input buffer using the entire input buffer and/or chunks as compression domains.
    Type: Application
    Filed: August 29, 2019
    Publication date: March 4, 2021
    Applicant: EMC IP HOLDING COMPANY LLC
    Inventors: Jeremy O'Hare, Kuolin Hua, Ken Dorman, Anoop Raghunathan, Jason Duquette, Lionel Bella, Alesia Tringale
  • Publication number: 20210026717
    Abstract: Embodiments of the present disclosure relate to an apparatus comprising a memory and at least one processor. The at least one processor is configured to: dynamically obtain a plurality of metadata from a global memory of a storage system; dynamically predict anticipated metadata based on the dynamically obtained metadata, wherein anticipated metadata is relevant to anticipated input/output (I/O) operations of the storage system; and dynamically instruct the storage system to load anticipated metadata into the global memory.
    Type: Application
    Filed: July 25, 2019
    Publication date: January 28, 2021
    Applicant: EMC IP Holding Company LLC
    Inventors: John Krasner, Jason Duquette
  • Patent number: 10853280
    Abstract: A storage system includes a storage engine having a first compute node, a second compute node, a first fabric adapter, and a second fabric adapter, the first compute node having a first memory and the second compute node having a second memory. The first compute node is connected to both the first and second fabric adapters, and the second compute node is connected to both the second and first fabric adapters. Both fabric adapters are configured to perform atomic operations on a memory of its respective compute node, and each fabric adapter contains a multi-initiating module configured to enable both the first compute node and the second compute node to initiate memory access operations on its respective memory.
    Type: Grant
    Filed: November 22, 2019
    Date of Patent: December 1, 2020
    Assignee: EMC IP Holding Company LLC
    Inventors: James Guyer, Jason Duquette, Alesia Tringale, Julie Zhivich
  • Publication number: 20200048265
    Abstract: Substituted bicyclic heteroaryls and compositions containing them, for the treatment of general inflammation, arthritis, rheumatic diseases, osteoarthritis, inflammatory bowel disorders, inflammatory eye disorders, inflammatory or unstable bladder disorders, psoriasis, skin complaints with inflammatory components, chronic inflammatory conditions, including but not restricted to autoimmune diseases such as systemic lupus erythematosis (SLE), myestenia gravis, rheumatoid arthritis, acute disseminated encephalomyelitis, idiopathic thrombocytopenic purpura, multiples sclerosis, Sjoegren's syndrome and autoimmune hemolytic anemia, allergic conditions including all forms of hypersensitivity, The present invention also enables methods for treating cancers that are mediated, dependent on or associated with p110? activity, including but not restricted to leukemias, such as Acute Myeloid leukaemia (AML) Myelo-dysplastic syndrome (MDS) myelo-proliferative diseases (MPD) Chronic Myeloid Leukemia (CML) T-cell Acute Lympho
    Type: Application
    Filed: October 17, 2019
    Publication date: February 13, 2020
    Applicant: Amgen Inc.
    Inventors: Yi CHEN, Timothy D. CUSHING, Jason A. DUQUETTE, Felix GONZALEZ LOPEZ DE TURISO, Xiaolin HAO, Xiao HE, Brian S. LUCAS, Lawrence R. MCGEE, Andreas REICHELT, Robert M. RZASA, Jennifer L. SEGANISH, Youngsook SHIN, Dawei ZHANG
  • Publication number: 20190062276
    Abstract: The present invention provides MDM2 inhibitor compounds of Formula I, wherein the variables are defined above, which compounds are useful as therapeutic agents, particularly for the treatment of cancers. The present invention also relates to pharmaceutical compositions that contain an MDM2 inhibitor.
    Type: Application
    Filed: March 21, 2018
    Publication date: February 28, 2019
    Inventors: Michael D. Bartberger, Ana Gonzalez Buenrostro, Hilary Plake Beck, Xiaoqi Chen, Richard Victor Connors, Jeffrey Deignan, Jason A. Duquette, John Eksterowicz, Benjamin Fisher, Brian M. Fox, Jiasheng Fu, Zice Fu, Felix Gonzalez Lopez De Turiso, Michael W. Gribble, JR., Darin J. Gustin, Julie A. Heath, Xin Huang, XianYun Jiao, Michael G. Johnson, Frank Kayser, David John Kopecky, SuJen Lai, Yihong Li, Zhihong Li, Jiwen Liu, Jonathan D. Low, Brian S. Lucas, Zhihua Ma, Lawrence R. McGee, Joel McIntosh, Dustin L. McMinn, Julio C. Medina, Jeffrey Thomas Mihalic, Steven H. Olson, Yosup Rew, Philip M. Roveto, Daqing Sun, Xiaodong Wang, Yingcai Wang, Xuelei Yan, Ming Yu, Jiang Zhu
  • Publication number: 20180105532
    Abstract: Substituted bicyclic heteroaryls and compositions containing them, for the treatment of general inflammation, arthritis, rheumatic diseases, osteoarthritis, inflammatory bowel disorders, inflammatory eye disorders, inflammatory or unstable bladder disorders, psoriasis, skin complaints with inflammatory components, chronic inflammatory conditions, including but not restricted to autoimmune diseases such as systemic lupus erythematosis (SLE), myestenia gravis, rheumatoid arthritis, acute disseminated encephalomyelitis, idiopathic thrombocytopenic purpura, multiples sclerosis, Sjoegren's syndrome and autoimmune hemolytic anemia, allergic conditions including all forms of hypersensitivity, The present invention also enables methods for treating cancers that are mediated, dependent on or associated with p110? activity, including but not restricted to leukemias, such as Acute Myeloid leukaemia (AML) Myelo-dysplastic syndrome (MDS) myelo-proliferative diseases (MPD) Chronic Myeloid Leukemia (CML) T-cell Acute Lympho
    Type: Application
    Filed: December 13, 2017
    Publication date: April 19, 2018
    Applicant: Amgen Inc.
    Inventors: Yi CHEN, Timothy D. CUSHING, Jason A. DUQUETTE, Felix GONZALEZ LOPEZ DE TURISO, Xiaolin HAO, Xiao HE, Brian S. LUCAS, Lawrence R. MCGEE, Andreas REICHELT, Robert M. RZASA, Jennifer L. SEGANISH, Youngsook SHIN, Dawei ZHANG
  • Patent number: 9873704
    Abstract: Substituted bicyclic heteroaryls and compositions containing them, for the treatment of general inflammation, arthritis, rheumatic diseases, osteoarthritis, inflammatory bowel disorders, inflammatory eye disorders, inflammatory or unstable bladder disorders, psoriasis, skin complaints with inflammatory components, chronic inflammatory conditions, including but not restricted to autoimmune diseases such as systemic lupus erythematosis (SLE), myestenia gravis, rheumatoid arthritis, acute disseminated encephalomyelitis, idiopathic thrombocytopenic purpura, multiples sclerosis, Sjoegren's syndrome and autoimmune hemolytic anemia, allergic conditions including all forms of hypersensitivity, The present invention also enables methods for treating cancers that are mediated, dependent on or associated with p110? activity, including but not restricted to leukemias, such as Acute Myeloid leukaemia (AML) Myelo-dysplastic syndrome (MDS) myelo-proliferative diseases (MPD) Chronic Myeloid Leukemia (CML) T-cell Acute Lympho
    Type: Grant
    Filed: July 26, 2016
    Date of Patent: January 23, 2018
    Assignee: AMGEN INC.
    Inventors: Minna Bui, Yi Chen, Timothy David Cushing, Jason A. Duquette, Benjamin Fisher, Felix Gonzalez Lopez De Turiso, Xiaolin Hao, Xiao He, Michael G. Johnson, Brian Lucas
  • Patent number: 9873701
    Abstract: Substituted bicyclic heteroaryls and compositions containing them, for the treatment of general inflammation, arthritis, rheumatic diseases, osteoarthritis, inflammatory bowel disorders, inflammatory eye disorders, inflammatory or unstable bladder disorders, psoriasis, skin complaints with inflammatory components, chronic inflammatory conditions, including but not restricted to autoimmune diseases such as systemic lupus erythematosis (SLE), myestenia gravis, rheumatoid arthritis, acute disseminated encephalomyelitis, idiopathic thrombocytopenic purpura, multiples sclerosis, Sjoegren's syndrome and autoimmune hemolytic anemia, allergic conditions including all forms of hypersensitivity, The present invention also enables methods for treating cancers that are mediated, dependent on or associated with p110? activity, including but not restricted to leukemias, such as Acute Myeloid leukaemia (AML) Myelo-dysplastic syndrome (MDS) myelo-proliferative diseases (MPD) Chronic Myeloid Leukemia (CML) T-cell Acute Lympho
    Type: Grant
    Filed: October 22, 2014
    Date of Patent: January 23, 2018
    Assignee: AMGEN INC.
    Inventors: Yi Chen, Timothy D. Cushing, Jason A. Duquette, Felix Gonzalez Lopez De Turiso, Xiaolin Hao, Xiao He, Brian S. Lucas, Lawrence R. McGee, Andreas Reichelt, Robert M. Rzasa, Jennifer L. Seganish, Youngsook Shin, Dawei Zhang
  • Publication number: 20170144971
    Abstract: The present invention provides MDM2 inhibitor compounds of Formula I, wherein the variables are defined above, which compounds are useful as therapeutic agents, particularly for the treatment of cancers. The present invention also relates to pharmaceutical compositions that contain an MDM2 inhibitor.
    Type: Application
    Filed: January 23, 2017
    Publication date: May 25, 2017
    Applicant: AMGEN INC.
    Inventors: Michael D. BARTBERGER, Ana GONZALEZ BUENROSTRO, Hilary Plake BECK, Xiaoqi CHEN, Richard Victor CONNORS, Jeffrey DEIGNAN, Jason A. DUQUETTE, John EKSTEROWICZ, Benjamin FISHER, Brian M. FOX, Jiasheng FU, Zice FU, Felix GONZALEZ LOPEZ DE TURISO, Michael W. GRIBBLE, Jr., Darin J. GUSTIN, Julie A. HEATH, Xin HUANG, XianYun JIAO, Michael G. JOHNSON, Frank KAYSER, David John KOPECKY, SuJen LAI, Yihong LI, Zhihong LI, Jiwen LIU, Jonathan D. LOW, Brian S. LUCAS, Zhihua MA, Lawrence R. MCGEE, Joel MCINTOSH, Dustin L. MCMINN, Julio C. MEDINA, Jeffrey Thomas MIHALIC, Steven H. OLSON, Yosup REW, Phillip M. ROVETO, Daqing SUN, Xiaodong WANG, Yingcai WANG, Xuelei YAN, Ming YU, Jiang ZHU
  • Patent number: 9593129
    Abstract: The present invention provides MDM2 inhibitor compounds of Formula I, wherein the variables are defined above, which compounds are useful as therapeutic agents, particularly for the treatment of cancers. The present invention also relates to pharmaceutical compositions that contain an MDM2 inhibitor.
    Type: Grant
    Filed: January 27, 2016
    Date of Patent: March 14, 2017
    Assignee: Amgen, Inc.
    Inventors: Michael D. Bartberger, Ana Gonzalez Buenrostro, Hilary Plake Beck, Xiaoqi Chen, Richard Victor Connors, Jeffrey Deignan, Jason A. Duquette, John Eksterowicz, Benjamin Fisher, Brian M. Fox, Jiasheng Fu, Zice Fu, Felix Gonzalez Lopez De Turiso, Michael W. Gribble, Jr., Darin J. Gustin, Julie A. Heath, Xin Huang, XianYun Jiao, Michael G. Johnson, Frank Kayser, David John Kopecky, SuJen Lai, Yihong Li, Zhihong Li, Jiwen Liu, Jonathan D. Low, Brian S. Lucas, Zhihua Ma, Lawrence R. McGee, Joel McIntosh, Dustin L. McMinn, Julio C. Medina, Jeffrey Thomas Mihalic, Steven H. Olson, Yosup Rew, Philip M. Roveto, Daqing Sun, Xiaodong Wang, Yingcai Wang, Xuelei Yan, Ming Yu, Jiang Zhu